NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more
NanoRepro AG (NN6) - Net Assets
Latest net assets as of June 2025: €37.30 Million EUR
Based on the latest financial reports, NanoRepro AG (NN6) has net assets worth €37.30 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€37.99 Million) and total liabilities (€694.21K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €37.30 Million |
| % of Total Assets | 98.17% |
| Annual Growth Rate | 37.33% |
| 5-Year Change | 377.35% |
| 10-Year Change | 1577.14% |
| Growth Volatility | 212.22 |
NanoRepro AG - Net Assets Trend (2008–2024)
This chart illustrates how NanoRepro AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NanoRepro AG (2008–2024)
The table below shows the annual net assets of NanoRepro AG from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €38.14 Million | -5.53% |
| 2023-12-31 | €40.38 Million | -14.88% |
| 2022-12-31 | €47.43 Million | -17.66% |
| 2021-12-31 | €57.61 Million | +621.00% |
| 2020-12-31 | €7.99 Million | +80.40% |
| 2019-12-31 | €4.43 Million | -21.16% |
| 2018-12-31 | €5.62 Million | +46.91% |
| 2017-12-31 | €3.82 Million | +26.01% |
| 2016-12-31 | €3.03 Million | +33.44% |
| 2015-12-31 | €2.27 Million | +19.25% |
| 2014-12-31 | €1.91 Million | +15.96% |
| 2013-12-31 | €1.64 Million | +90.74% |
| 2012-12-31 | €862.16K | +0.47% |
| 2011-12-31 | €858.14K | -45.30% |
| 2010-12-31 | €1.57 Million | +671.10% |
| 2009-12-31 | €203.45K | -14.62% |
| 2008-12-31 | €238.29K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NanoRepro AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 430309438.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €3.08 Million | 8.08% |
| Common Stock | €12.90 Million | 33.83% |
| Other Components | €22.16 Million | 58.09% |
| Total Equity | €38.14 Million | 100.00% |
NanoRepro AG Competitors by Market Cap
The table below lists competitors of NanoRepro AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Peninsula Land Limited
NSE:PENINLAND
|
$16.84 Million |
|
B3 CONSULTING GRP AB O.N.
F:B37
|
$16.85 Million |
|
Flux Power Holdings Inc
NASDAQ:FLUX
|
$16.85 Million |
|
NETWORK-1 TECH.INC.DL-01
F:6LK
|
$16.85 Million |
|
SKINBIO THERAP LS-01
F:5KW
|
$16.83 Million |
|
Inin Group A/S
OL:ININ
|
$16.82 Million |
|
FNC Entertainment Co Ltd
KQ:173940
|
$16.82 Million |
|
Anteotech Ltd
AU:ADO
|
$16.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NanoRepro AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,375,872 to 38,141,276, a change of -2,234,596 (-5.5%).
- Net loss of 2,045,757 reduced equity.
- Share repurchases of 188,800 reduced equity.
- Other comprehensive income decreased equity by 22,446,205.
- Other factors increased equity by 22,446,166.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.05 Million | -5.36% |
| Share Repurchases | €188.80K | -0.5% |
| Other Comprehensive Income | €-22.45 Million | -58.85% |
| Other Changes | €22.45 Million | +58.85% |
| Total Change | €- | -5.53% |
Book Value vs Market Value Analysis
This analysis compares NanoRepro AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.94x to 0.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | €0.21 | €1.45 | x |
| 2009-12-31 | €0.18 | €1.45 | x |
| 2010-12-31 | €1.37 | €1.45 | x |
| 2011-12-31 | €0.75 | €1.45 | x |
| 2012-12-31 | €0.75 | €1.45 | x |
| 2013-12-31 | €0.19 | €1.45 | x |
| 2014-12-31 | €0.22 | €1.45 | x |
| 2015-12-31 | €0.52 | €1.45 | x |
| 2016-12-31 | €0.54 | €1.45 | x |
| 2017-12-31 | €0.56 | €1.45 | x |
| 2018-12-31 | €0.66 | €1.45 | x |
| 2019-12-31 | €0.51 | €1.45 | x |
| 2020-12-31 | €0.86 | €1.45 | x |
| 2021-12-31 | €4.46 | €1.45 | x |
| 2022-12-31 | €3.68 | €1.45 | x |
| 2023-12-31 | €3.18 | €1.45 | x |
| 2024-12-31 | €3.02 | €1.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NanoRepro AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.02%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.02x
- Recent ROE (-5.36%) is above the historical average (-57.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -330.81% | -1170.94% | 0.16x | 1.82x | €-812.12K |
| 2009 | -216.68% | -194.37% | 0.50x | 2.21x | €-461.17K |
| 2010 | -41.31% | -206.49% | 0.16x | 1.24x | €-804.93K |
| 2011 | -209.10% | -215.79% | 0.83x | 1.16x | €-1.88 Million |
| 2012 | -68.37% | -63.05% | 0.88x | 1.23x | €-675.70K |
| 2013 | -30.27% | -47.78% | 0.58x | 1.09x | €-662.14K |
| 2014 | -1.42% | -2.58% | 0.48x | 1.14x | €-217.70K |
| 2015 | -51.70% | -193.50% | 0.25x | 1.07x | €-1.40 Million |
| 2016 | -18.18% | -29.78% | 0.53x | 1.16x | €-855.14K |
| 2017 | -19.20% | -37.23% | 0.47x | 1.10x | €-1.12 Million |
| 2018 | -5.16% | -10.54% | 0.47x | 1.03x | €-851.39K |
| 2019 | -26.84% | -97.56% | 0.25x | 1.08x | €-1.63 Million |
| 2020 | 21.21% | 10.01% | 1.52x | 1.40x | €895.92K |
| 2021 | 51.59% | 18.27% | 2.06x | 1.37x | €23.96 Million |
| 2022 | -7.85% | -9.68% | 0.78x | 1.04x | €-8.47 Million |
| 2023 | -11.60% | -147.17% | 0.08x | 1.03x | €-8.72 Million |
| 2024 | -5.36% | -44.02% | 0.12x | 1.02x | €-5.86 Million |
Industry Comparison
This section compares NanoRepro AG's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $12,326,296,000
- Average return on equity (ROE) among peers: -45.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NanoRepro AG (NN6) | €37.30 Million | -330.81% | 0.02x | $16.84 Million |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |